Novartis loses emergency bid to block Entresto generic in US
Portfolio Pulse from
A federal judge in Washington, D.C. has denied Novartis' attempt to prevent MSN Pharmaceuticals from launching a generic version of its heart-failure drug, Entresto.
January 16, 2025 | 12:15 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Novartis' legal attempt to block a generic version of its heart-failure drug Entresto has been denied, potentially impacting its market share and revenues.
The denial of Novartis' bid to block a generic version of Entresto could lead to increased competition and reduced market share for Novartis, negatively impacting its revenues from this blockbuster drug.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90